Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulgent Genetics surpasses revenue targets, eyes precision medicine growth

Fulgent Genetics delivered strong financial performance in 2022, exceeding revenue guidance and positioning for continued growth in 2023 across key business segments.
The company's strategic focus on precision medicine, oncology, and pharma services, coupled with a robust cash position, sets the stage for future expansion and innovation.
Challenges in margin improvement and reimbursement highlight areas for operational refinement, while opportunities in acquisitions and menu expansion offer avenues for sustained growth.

Fulgent Genetics reports robust Q1 revenue growth and strategic advancements

Fulgent Genetics delivered strong revenue growth in Q1 2023, with a focus on core business strength and promising developments in key drug candidates and business segments.
While facing challenges in operational efficiency and negative Adjusted EBITDA, the company maintains a strong cash position and is optimistic about future opportunities.
Strategic acquisitions, market expansion, and continued margin improvement are key areas of focus for Fulgent Genetics to drive sustained growth and profitability.

Fulgent Genetics reports record Q2 revenue and advances in cancer treatment

Fulgent Genetics (FLGT) delivered a strong performance in Q2 2023, with record core revenue and promising developments in cancer treatment.
The company's focus on innovation, operational efficiency, and margin improvement underscores a commitment to sustainable growth.
While facing challenges in cost management and competitive dynamics, Fulgent Genetics is well-positioned to capitalize on opportunities through technology and strategic initiatives.

Fulgent Genetics reports robust Q3 earnings, eyes growth in precision diagnostics

Fulgent Genetics demonstrated solid financial performance in Q3 2023, with strong core revenue and improved gross margins. The company continues to focus on precision diagnostics and therapeutic development, presenting growth opportunities. Challenges include fluctuations in Pharma services revenue and COVID-19 testing demand.

Fulgent Genetics surpasses Q4 revenue targets, eyes FDA regulatory landscape

Fulgent Genetics delivered strong Q4 results, exceeding revenue guidance and showcasing growth in core revenue.
The company faces challenges in BioPharma Services and Anatomic Pathology but is investing in operations and AI for improvement.
Opportunities lie in Precision Diagnostics growth, market share gains in carrier screening, and adapting to FDA oversight of laboratory developed tests.
Management's confidence in quality systems and readiness to pursue FDA approval for high-risk tests position Fulgent Genetics for regulatory changes.

Fulgent Genetics excels in Q1 2024 with strong revenue growth

Fulgent Genetics delivered strong Q1 results driven by precision diagnostics and therapeutic development progress.
While facing challenges in managing expenses, the company showcased financial discipline and innovation in new product launches.
With a focus on improving margins and capturing market opportunities, Fulgent Genetics aims for continued growth and profitability in 2024.

Fulgent Genetics reports robust Q2 revenue, invests in innovative treatments

Fulgent Genetics demonstrated solid revenue performance in Q2, driven by core business growth in key segments.
While facing profitability challenges, the company continues to invest in innovative treatments and technology.
Maintaining a strong cash position and focusing on strategic growth areas position Fulgent Genetics for future success.
Balancing cost management with revenue growth will be crucial for the company's financial health and long-term sustainability.

Fulgent Genetics reports robust Q3 earnings, eyes strategic growth opportunities

Fulgent Genetics demonstrated solid revenue growth and financial stability in Q3 2024.
The company's focus on precision diagnostics and therapeutic development shows promise for future growth.
Challenges lie in maintaining margins, managing expenses, and optimizing the VA contract's impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

AmerisourceBergen

Hedging against COVID-19 could prove to be crucial in keeping your portfolio safe.

2 Types of Growth Stocks Investors Should Be Holding in Their Portfolios Today

Spectacular quarterly results were not enough to satisfy investors' appetites.

Why Shares of Fulgent Genetics Are Plunging Today

Fulgent Genetics reported earnings recently, on August 9th, 2021. Fulgent dropped nearly 15% after the earnings report, likely due to misses on both revenue and EPS estimates.

Fulgent Genetics Misses Estimates, But I Am Still Bullish

Fulgent Genetics Inc (NASDAQ: FLGT) reported after the close of the market on Monday that its second-quarter revenues increased nearly ninefold, driven primarily by increased test volumes. Revenues skyrocketed to $153.6 million from $17.3 million in Q2 of 2020 but missed the consensus of $197.3 million.

Fulgent Genetics Stock Falls As Q2 Earnings Miss Street Estimates; Lowers FY21 Sales Outlook

The stock price of Fulgent Genetics Inc (NASDAQ: FLGT) fell by over 15% pre-market. This is why it happened.

FLGT Stock Price Falls Over 15% Pre-Market: Why It Happened

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q2 2021 Results - Earnings Call Transcript

FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of -0.78% and -21.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

FULGENT GENETIC (FLGT) Q2 Earnings and Revenues Miss Estimates

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2021. Second Quarter 2021 Results: Revenue of $153.6 million, growing 790% year-over-year Billable tests delivered approximately 1.6 million, or 9 times the volume of second

Fulgent Genetics Reports Second Quarter Financial Results

TEMPLE CITY, Calif. & IRVINE, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, and Helio Health (“Helio”), an AI-biotechnology company developing blood-based early cancer detection tests, today announced the companies have entered into a strategic partnership to commercialize Helio's blood-based early canc

Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has acquired CSI Laboratories (“CSI”) to expand its presence in somatic molecular diagnostics and cancer testing. CSI was founded in 1997 to provide a client- and patient-focused model of cancer diagnostic testing for pat

Fulgent Genetics Announces Acquisition of CSI Laboratories

In the latest trading session, FULGENT GENETIC (FLGT) closed at $110.87, marking a +0.33% move from the previous day.

FULGENT GENETIC (FLGT) Gains But Lags Market: What You Should Know

Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.

What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?

FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FULGENT GENETIC (FLGT) Reports Next Week: Wall Street Expects Earnings Growth

Big 5 Sporting Goods

China Yuchai International Limited

Extremely cheap stocks that have momentum can offer astonishing returns. Here are two worth keeping a close eye on.

2 Stocks that Could be the Next GME or AMC

In the latest trading session, FULGENT GENETIC (FLGT) closed at $92.25, marking a +0.36% move from the previous day.

FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know

FuboTV

Tattooed Chef

It may be curtains for the apes' high-profile, most-shorted stocks, but others may become the real deal with other bullish investors. The post 3 Smaller Most-Shorted Stocks to Buy appeared first on InvestorPlace.

3 Smaller Most-Shorted Stocks to Buy

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--In the headline and first paragraph, first sentence of release, the date should read: Monday, August 9, 2021 (instead of Thursday, August 5, 2021). The updated release reads: FULGENT GENETICS TO ANNOUNCE SECOND QUARTER 2021 FINANCIAL RESULTS ON MONDAY, AUGUST 9, 2021 Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today annou

CORRECTING and REPLACING Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. The company's Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chi

Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021

The stock has traded with the ebbs and flows of COVID cases, but its testing has consistently delivered for its impressive list of customers.

Why Shares of Fulgent Genetics Rose 77% in the First Half of 2021

Few companies had bigger tailwinds from COVID-19. What comes next could be even more exciting.

3 Things About Fulgent Genetics That Smart Investors Know

Abbott Labs

BioNTech SE

Lucira Health

Roche Holding AG

Despite easing restrictions, COVID is going to be around a lot longer than many think.

5 Stocks to Own for the Surge in Coronavirus Variants

Roku

Take-Two Interactive Software

A steep sell-off is required for these stocks to become bargain buys.

3 Stocks I'd Buy if the Market Crashes

FULGENT GENETIC (FLGT) closed the most recent trading day at $85.94, moving -0.13% from the previous trading session.

FULGENT GENETIC (FLGT) Stock Moves -0.13%: What You Should Know

Albertsons Companies

Altimeter Growth

Blink Charging

Clover Health Investments

Esperion Therapeutics

Arcimoto

Canoo

Nikola

Workhorse Group

Gogo

Pubmatic

Investors are seeking out the most highly shorted stocks. With GME and AMC seeing monolithic gains, can the same thing be done elsewhere?

12 Most Highly Shorted Stocks Heading Into Q3 2021

FULGENT GENETIC (FLGT) closed at $87.17 in the latest trading session, marking a -0.31% move from the prior day.

News for Fulgent Genetics Stock (FLGT)